Regulatory T cells in cancer: where are we now?
Open Access
- 21 June 2019
- journal article
- editorial
- Published by Wiley in Immunology
- Vol. 157 (3) , 187-189
Abstract
Summary: There have been substantial strides forward in our understanding of the contribution of regulatory T (Treg) cells to cancer immunosuppression. In this issue, we present a series of papers highlighting emerging themes on this topic relevant not only to our understanding of the fundamental biology of tumour immunosuppression but also to the design of new immunotherapeutic approaches. The substantially shared biology of CD4+ conventional T (Tconv) and Treg cells necessitates a detailed understanding of the potentially opposing functional consequences that immunotherapies will have on Treg and Tconv cells, a prominent example being the potential for Treg‐mediated hyperprogressive disease following anti‐PD‐1 therapy. Such understanding will aid patient stratification and the rational design of combination therapies. It is also becoming clear, however, that Treg cells within tumours exhibit distinct biological features to both Tconv cells and Treg cells in other tissues. These distinct features provide the opportunity for development of targeted immunotherapies with greater efficacy and reduced potential for inducing systemic toxicity.Keywords
Funding Information
- Wellcome Trust (105663/Z/14/Z)
- Biotechnology and Biological Sciences Research Council (BB/N007794/1)
- Cancer Research UK (C52623/A22597)
- Medical Research Council
This publication has 29 references indexed in Scilit:
- The interplay of effector and regulatory T cells in cancerCurrent Opinion in Immunology, 2015
- Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapyJournal of Experimental Medicine, 2013
- Regulatory T Cells: Mechanisms of Differentiation and FunctionAnnual Review of Immunology, 2012
- Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradicationImmunological Reviews, 2011
- Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established MelanomaCancer Research, 2010
- Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor GrowthCancer Research, 2010
- Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell DepletionCancer Research, 2010
- Regulatory T Cells and Immune ToleranceCell, 2008
- Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patientsCancer, 2006
- Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late RelapseJournal of Clinical Oncology, 2006